SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
 
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Majors Cary L

(Last) (First) (Middle)
C/O 70 SIR JOHN ROGERSON'S QUAY

(Street)
DUBLIN L2 2

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
05/07/2019
3. Issuer Name and Ticker or Trading Symbol
STERIS plc [ STE ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
VP, N America Com Operations
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares 18,020(1) D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) (2) 05/28/2025 Ordinary Shares 2,250 66.15 D
Employee Stock Option (right to buy) (3) 06/01/2026 Ordinary Shares 6,000 69.72 D
Employee Stock Option (right to buy) (4) 05/31/2028 Ordinary Shares 14,932 114.22 D
Explanation of Responses:
1. 18,020 of these shares are restricted. The restrictions on the ordinary shares lapse as follows: 2,000 on May 28, 2019; 1,500 on May 28, 2019; 3,000 on October 1, 2019; 2,500 on June 1, 2020; 6,500 on May 31, 2021 and 2,520 on May 31, 2022.
2. This option becomes exercisable as follows: 2,250 on May 28, 2016; 2,250 on May 30, 2017; 2,250 on May 29, 2018 and 2,250 on May 28, 2019. This option was received under the Scheme in exchange for an option to purchase 9,000 STERIS ordinary shares for $66.15 per share, subject to the same terms and conditions as the original Old STERIS stock option.
3. This option becomes exercisable as follows: 3,000 on June 1, 2017; 3,000 on June 1, 2018; 3,000 on June 3, 2019 and 3,000 on June 1, 2020. This option was received under the Scheme in exchange for an option to purchase 12,000 STERIS ordinary shares for $69.72 per share, subject to the same terms and conditions as the original Old STERIS stock option.
4. This option becomes exercisable as follows: 3,733 on May 31, 2019; 3,733 on June 1, 2020; 3,733 on June 1, 2021 and 3,733 on May 31, 2022. This option was received under the Scheme in exchange for an option to purchase 14,932 STERIS ordinary shares for $114.22 per share, subject to the same terms and conditions as the original Old STERIS stock option.
Remarks:
/s/ Ronald E. Snyder, Authorized Representative under Power of Attorney 05/16/2019
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Securities and Exchange Commission Washington, D.C. 20549

RE:	STERIS plc
1933 Act and 1934 Act Filings
Authorized Representatives
Ladies and Gentlemen:

The above Company, a public limited company organized under the laws of
Ireland, is or will be the issuer of securities registered under Section 12
of the Securities Exchange Act of 1934. The undersigned confirms, as of the
date appearing opposite his/her signature, that each of the "Authorized
Representatives" named below is authorized on his/her behalf to sign such
statements (on Form 3, Form 4, Form 5, Form 144, Schedule 13G, Form ID (if
necessary) or otherwise, collectively, "Forms") with respect to securities of
the Company (the "Securities"), and to submit to the Securities and Exchange
Commission such Forms (including reports, notices, and other statements) with
respect to the Securities, as are required by the Securities Act of 1933, as
amended, or the Securities Exchange Act of 1934 as amended (collectively, the
"Acts").  The undersigned also confirms the authority of each of the Authorized
Representatives to do and perform, on his/her behalf, any and all acts and
things with respect to the Securities requisite or necessary to assure
compliance by the undersigned with the filing requirements of the Acts.

This authority revokes all prior authorities with respect to the Securities
previously executed by the undersigned including but not limited to any such
authorities filed with or given to the Commission by the undersigned. This
authority contained herein shall remain in full force and effect until the
undersigned is no longer required to file Forms with respect to the
undersigned's holdings of and transactions in the Securities, unless earlier
revoked by the undersigned in a signed writing delivered to the Authorized
Representatives.

Authorized Representatives
Patricia Comai
Judith A. Hunter
Julia Kipnis
Rebecca A. Nichols
Ronald E. Snyder
Michael J. Tokich
J. Adam Zangerle

The undersigned acknowledges that the foregoing Authorized Representatives, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to
comply with the Acts.  Additionally, although pursuant to this authority, the
Authorized Representatives will use commercially reasonable efforts to timely
and accurately file the required Forms on behalf of the undersigned, the
Authorized Representatives do not represent or warrant that they will be able
to in all cases timely and accurately file such Forms on behalf of the
undersigned due to various factors and the undersigned and the Authorized
Representatives' need to rely on others forinformation, including the
undersigned and brokers of the undersigned.


Dated: May 7, 2019               By: /s/ Cary L. Majors
                                        Signature

                                        Printed Name
                                        Cary L. Majors
















Shareholder Tools